Zika virus vaccine

Patent metadata

Field	Value
Publication number	US-11219681-B2
Application number	US-202016813862-A
Country	US
Kind code	B2
Filing date	Mar 10, 2020
Priority date	Dec 23, 2015
Publication date	Jan 11, 2022
Grant date	Jan 11, 2022

Abstract

Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

First claim

What is claimed is:

1. A Zika virus vaccine comprising a Zika virus having an RNA genome corresponding to the DNA sequence provided by SEQ ID NO: 72 or a variant nucleic acid having at least 80% identity to SEQ ID NO: 72, wherein said Zika virus vaccine is capable of stimulating a neutralizing antibody titer greater than 15 in at least 70% of vaccinated subjects, wherein the neutralizing antibody titer is determined using a microneutralization assay (MN 50 ).

2. The Zika virus vaccine according to claim 1 , wherein said MN 50 is greater than 20, 25, 30, 35, 40, or 45.

3. The Zika virus vaccine according to claim 1 , wherein the Zika virus vaccine is capable of stimulating a MN 50 titer greater than 15 in at least 75%, 80%, 90%, 95%, 96%, 97%, 98%, or at least 99% of vaccinated subjects.

4. The Zika virus vaccine according to claim 1 , wherein the Zika virus comprises an E protein having an amino acid sequence provided by any one of SEQ ID NOs: 14-69, or a variant amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 14-69 and able to pack a virulent Zika virus.

5. The Zika virus vaccine according to claim 1 , wherein the Zika virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

6. The Zika virus vaccine according to claim 5 , wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent for longer than is required to completely inactivate the Zika virus as measured by plaque assay.

7. The Zika virus vaccine according to claim 5 , wherein the chemical inactivation comprises contacting the Zika virus with formaldehyde.

8. The Zika virus vaccine according to claim 7 , wherein the chemical inactivation comprises contacting the Zika virus with formaldehyde for between 2-10 days.

9. The Zika virus vaccine according to claim 5 , wherein the chemical activation is performed at about +4° C. or about +22° C.

10. The Zika virus vaccine according to claim 1 , further comprising an adjuvant.

11. The Zika virus vaccine according to claim 10 , wherein the adjuvant is an aluminium salt adjuvant.

12. The Zika virus vaccine according to claim 11 , wherein said aluminium salt adjuvant is aluminium hydroxide with less than 1.25 parts per billion (ppb) copper (Cu) based on a final pharmaceutical composition comprising the Zika virus.

13. The Zika virus vaccine according to claim 10 , wherein the adjuvant comprises a peptide and a deoxyinosine-containing immunostimulatory oligodeoxynucleic acid molecule (I-ODN).

14. The Zika virus vaccine according to claim 13 , wherein the peptide comprises the sequence KLKL 5 KLK (SEQ ID NO: 71) and the I-ODN comprises oligo-d(IC) 13 (SEQ ID NO: 70).

15. The Zika virus vaccine according to claim 1 , further comprising one or more pharmaceutically acceptable excipients.

16. The Zika virus vaccine according to claim 1 , wherein the vaccine comprises protamine sulphate (PS) or fragments or break-down products of PS at amounts below the limits of detection by high performance liquid chromatography (HPLC).

17. The Zika virus vaccine according to claim 16 , wherein said PS or fragments or break-down products of PS are detectable by mass spectroscopy.

18. A method for purifying infectious Zika virus, comprising the steps of
i) providing a crude harvest (a) comprising infectious Zika virus particles, non-infectious Zika virus particles, and impurities, wherein the impurities are generated from growing said Zika virus on a cell substrate;
ii) contacting said crude harvest (a) with an agent comprising protamine to obtain a Zika virus preparation (b) comprising infectious Zika virus particles; and
iii) further purifying said Zika virus preparation (b) by one or more size exclusion methods, wherein said one or more size exclusion methods comprise
(A) sucrose density gradient centrifugation,
(B) a solid-phase matrix packed in a column comprising a ligand-activated core and an inactive shell comprising pores, wherein the pores comprise a molecular weight cut-off that excludes the virus particles from entering the ligand-activated core, and wherein a molecule smaller than the molecular weight cut-off of the pores can enter the ligand-activated core, and/or
(C) size exclusion chromatography;
to obtain a purified Zika virus preparation (c) comprising infectious Zika virus particles, less than 100 ng/mL residual host cell DNA, less than 1 μg/mL residual host cell protein, and less than 1 μg/mL residual aggregates of virus particles.

19. The method according to claim 18 , wherein the purified Zika virus preparation (c) comprises less than 10 ng/mL residual host cell DNA and less than 100 ng/mL residual host cell protein.

20. The method according to claim 18 , wherein said crude harvest (a) is subjected to one or more pre-purification step(s) prior to step ii), wherein the one or more pre-purification step(s) comprise
filtration using a filter having a pore size equal to or less than 0.2 μm,
digestion of host cell genomic DNA by enzymatic treatment, and/or
ultra/diafiltration using a hollow fiber membrane having a pore size equal to or greater than 100 kDa.

21. The Zika virus vaccine according to claim 1 , wherein said variant nucleic acid has at least 90% identity to SEQ ID NO: 72.

22. The Zika virus vaccine according to claim 1 , wherein said variant nucleic acid has at least 95% identity to SEQ ID NO: 72.

23. The Zika virus vaccine according to claim 1 , wherein said variant nucleic acid has at least 99% identity to SEQ ID NO: 72.

24. The Zika virus vaccine according to claim 2 , wherein said MN50 is greater than 50, 55, 60, 65, 70, 75, 80, or 85.

25. The Zika virus vaccine according to claim 2 , wherein said MN50 is greater or equal to 90.

26. The Zika virus vaccine according to claim 1 , wherein the vaccine comprises protamine sulphate (PS) or fragments or break-down products of PS at amounts below 1 μg/mL or below 100 ng/mL.

Assignees

• Valneva Austria Gmbh

Inventors

• Barbero Calzado Jana
• Nebenführ Mario
• Schlegl Robert
• Weber Michael
• Heindl-Wruss Jürgen

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• C12N2770/24163

  by chemical treatment · CPC title

• C12N2770/24134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K2039/55561

  CpG containing adjuvants; Oligonucleotide containing adjuvants · CPC title

• A61K2039/55516

  Proteins; Peptides · CPC title